Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

28.08.17	Lilly to Participate in Morgan Stanley Global Healthcare Conference (PR Newswire)
17.08.17	Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi (PR Newswire)
04.08.17	Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study (RTTNews)
04.08.17	Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine (PR Newswire)
31.07.17	Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular... (PR Newswire)
26.07.17	Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX (RTTNews)
25.07.17	MÄRKTE USA/Gute Quartalsberichte treiben S&P-500 auf Rekordhoch (Dow Jones)
25.07.17	MÄRKTE USA/Gute Quartalsberichte treiben S&P-500 -2- (Dow Jones)
25.07.17	MÄRKTE USA/Positive Geschäftsberichte stützen Wall Street (Dow Jones)
25.07.17	MÄRKTE USA/Wall Street mit Berichtsperiode etwas fester erwartet (Dow Jones)
25.07.17	Neue Arzneien und Preiserhöhungen treiben Eli Lilly an (AWP) Der US-Pharmakonzern Eli Lilly hat im zweiten Quartal von einer guten Nachfrage nach noch recht neuen Medikamenten profitiert.» mehr
25.07.17	Eli Lilly Raises 2017 Non-GAAP EPS Guidance - Quick Facts (RTTNews)
25.07.17	Eli Lilly And Co. Reports 30% Advance In Q2 Profit (RTTNews)
25.07.17	Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib (RTTNews)
25.07.17	Lilly Reports Second-Quarter Results (PR Newswire)
25.07.17	Lilly and Incyte Provide Update on Baricitinib (PR Newswire)
24.07.17	MÄRKTE USA/Nasdaq-Indizes auf Allzeithoch - Quartalszahlen im Fokus (Dow Jones)
24.07.17	MÄRKTE USA/US-Wachstumsprognose des IWF bremst Wall Street (Dow Jones)
24.07.17	Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358 (RTTNews)
24.07.17	Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy (PR Newswire)
12.07.17	Lilly Reaches Settlement Deal In US Cialis Patent Litigation (RTTNews)
12.07.17	Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation (PR Newswire)
12.07.17	Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017) (PR Newswire)
10.07.17	Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment (PR Newswire)
10.07.17	Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment (PR Newswire)
10.07.17	Lilly: FDA Files NDA For Abemaciclib For Treatment Of Advanced Breast Cancer (RTTNews)
10.07.17	FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer (PR Newswire)
07.07.17	UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents (RTTNews)
07.07.17	UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents (PR Newswire)
06.07.17	Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement (PR Newswire)
06.07.17	Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts (RTTNews)
05.07.17	Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi (PR Newswire)
03.07.17	Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts (RTTNews)
03.07.17	Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis (PR Newswire)
28.06.17	Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications (PR Newswire)
27.06.17	Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications (PR Newswire)
27.06.17	Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour (PR Newswire)
21.06.17	Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego (PR Newswire)
19.06.17	Lilly Declares Third-Quarter 2017 Dividend (PR Newswire)
19.06.17	Lilly and NRAS Launch New Film for RA Awareness Week to Reveal the True Impact of RA (PR Newswire)
16.06.17	Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib (RTTNews)
16.06.17	Eli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial (RTTNews)
16.06.17	EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks (PR Newswire)
16.06.17	New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 (PR Newswire)
16.06.17	Eli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis (PR Newswire)
16.06.17	ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits (RTTNews)
15.06.17	Lilly's Taltz Shows Improvements In Disease Signs And Symptoms In PsA (RTTNews)
15.06.17	EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’282.00	1.18 %	K V
Kuehne+Nagel Int	203.50	0.44 %	K V
Alcon	76.50	0.24 %	K V
Holcim	89.00	0.16 %	K V
ABB	51.88	0.00 %	K V
Sika	223.80	-1.06 %	K V
Swisscom	501.50	-1.08 %	K V
Swiss Re	129.70	-1.71 %	K V
Givaudan	3’981.00	-1.97 %	K V
Nestle	73.72	-1.99 %	K V

mehr

12:26		Börse Europa in Grün: Euro STOXX 50 steigt mittags
12:26		Börse Zürich: SMI präsentiert sich leichter
09:29		Verluste in Europa: Euro STOXX 50 beginnt die Mittwochssitzung im Minus
09:29		Verluste in Zürich: SMI beginnt Mittwochshandel im Minus
09:29		Optimismus in Frankfurt: DAX zum Handelsstart fester
09:29		Pluszeichen in Frankfurt: Anleger lassen LUS-DAX zum Start steigen
17.12.24		Schwache Performance in New York: S&P 500 beendet den Handel im Minus
17.12.24		Pfizer-Aktie unverändert: Umsatz auf Vorjahreshöhe für 2025 geplant

12:26

Börse Europa in Grün: Euro STOXX 50 steigt mittags

12:26

Börse Zürich: SMI präsentiert sich leichter

09:29

Verluste in Europa: Euro STOXX 50 beginnt die Mittwochssitzung im Minus

09:29

Verluste in Zürich: SMI beginnt Mittwochshandel im Minus

09:29

Optimismus in Frankfurt: DAX zum Handelsstart fester

09:29

Pluszeichen in Frankfurt: Anleger lassen LUS-DAX zum Start steigen